Program Overview: Broadview is a philanthropic venture firm founded in 2009 and funded by the Leducq Family Trust. Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. They define cardiovascular broadly to include heart and peripheral vascular disease, valvular disorders, cardio-renal, hypertension and stroke (neurovascular). They also invest in metabolic disease as it relates to cardiovascular risk factors(type 2 diabetes, obesity, dislipidemia metabolic syndrome.) While therapeutically focused Broadview invests across technologies to include drugs, devices, diagnostics, and regenerative therapies.
Broadview Ventures is searching for early stage innovators developing diverse therapeutics and technologies focusing on cardiovascular, metabolic, and neurovascular disease.
Join Johnson and Johnson Innovation, JLABS for an overview presentation of Broadview Ventures' unique investment strategies. Christopher De Souza, Director of Broadview Ventures will be in attendance to present the company’s key areas of interests. Following the presentation, Christopher will answer any questions and meet one-on-one with approved applicants.
Christopher de Souza | Director, Broadview Ventures
The one-on-one application period will close on March 19, 2018. Your application will be reviewed and you will be notified of acceptance by April 3, 2018. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.